Compare Fox Corp Class B (FOX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Novo Nordisk A/S — how do they compare? Fox Corp Class B trades at $49.77 (market cap $22.28B), while Novo Nordisk A/S trades at $51.45 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 10× Fox Corp Class B's market cap, and Novo Nordisk A/S pays the higher dividend (3.56%). Which is the better fit depends on your goals.
| FOX | NVO | |
|---|---|---|
Market Cap | $22.28B | $222.24B |
Sector | Media | Health |
52-Week High | $67.76 | $71.70 |
52-Week Low | $44.39 | $35.29 |
Enterprise Value | $26.25B | $241.20B |
Dividend Yield | 1.11% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOX) trades at $51.06, up 3.15% with strong recent earnings beats. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Fundamentally, the company delivered robust 2025 results with $16.3B revenue and $2.26B net income, supported by improved cash flow generation. Recent news highlights Fox's strategic positioning in streaming and advertising growth.
Fox presents a compelling value opportunity with reasonable valuation multiples (P/E 13.26, P/S 1.39) and consistent earnings outperformance. However, technical weakness and competitive pressures in media streaming require monitoring. Analyst consensus leans positive with 42.86% buy ratings, though execution risks in the Roku integration and advertising market volatility remain key considerations.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
